Lista de obras - Jan Philipp Bewersdorf - Dominio Público Uruguay

Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?

scientific article published on 17 January 2019

Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents

artículo científico publicado en 2019

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis

scientific article published on 24 December 2019

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience

scientific article published on 02 May 2020

Early and aggressive ISR with a polymer- and carrier-free drug-coated stent system.

artículo científico publicado en 2017

Emerging treatment options for patients with high-risk myelodysplastic syndrome

scientific article published on 11 November 2020

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?

artículo científico publicado en 2019

Evolving therapies for lower-risk myelodysplastic syndromes

artículo científico publicado en 2020

Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?

scientific article published on 18 May 2020

Generic atorvastatin is as effective as the brand-name drug (LIPITOR®) in lowering cholesterol levels: a cross-sectional retrospective cohort study

artículo científico publicado en 2017

Getting personal with myelodysplastic syndromes: is now the right time?

scientific article published on 12 April 2019

Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes

artículo científico publicado en 2020

Healthcare expenses for treatment of acute myeloid leukemia

scientific article published on 13 June 2019

Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia

scientific article published on 17 August 2019

High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis

artículo científico publicado en 2020

Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?

artículo científico publicado en 2020

Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†

scientific article published on 26 December 2019

Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled

scientific article published on 19 March 2019

Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis

scientific article published on 01 September 2020

Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought?

scientific article published on 26 April 2020

Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-A systematic review and meta-analysis

artículo científico publicado en 2020

Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits

scientific article published on 04 April 2020

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?

artículo científico publicado en 2020

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study

artículo científico publicado en 2020

Mast Cells Are Activated by Streptococcus pneumoniae In Vitro but Dispensable for the Host Defense Against Pneumococcal Central Nervous System Infection In Vivo.

artículo científico publicado en 2018

Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era

artículo científico publicado en 2020

Novel and preclinical treatment strategies in pneumococcal meningitis.

artículo científico publicado en 2017

One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopo

scientific article published on 26 June 2019

Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy

artículo científico publicado en 2020

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

scientific article published on 18 June 2020

Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis

scientific article published on 04 September 2019

The SPEED (sepsis patient evaluation in the emergency department) score: a risk stratification and outcome prediction tool

artículo científico publicado en 2015

Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes

artículo científico publicado en 2019

Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey

artículo científico publicado en 2020

Lista de obras de Jan Philipp Bewersdorf

Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?

Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience

Early and aggressive ISR with a polymer- and carrier-free drug-coated stent system.

Emerging treatment options for patients with high-risk myelodysplastic syndrome

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?

Evolving therapies for lower-risk myelodysplastic syndromes

Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?

Generic atorvastatin is as effective as the brand-name drug (LIPITOR®) in lowering cholesterol levels: a cross-sectional retrospective cohort study

Getting personal with myelodysplastic syndromes: is now the right time?

Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes

Healthcare expenses for treatment of acute myeloid leukemia

Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia

High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis

Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?

Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†

Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled

Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis

Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought?

Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-A systematic review and meta-analysis

Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study

Mast Cells Are Activated by Streptococcus pneumoniae In Vitro but Dispensable for the Host Defense Against Pneumococcal Central Nervous System Infection In Vivo.

Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era

Novel and preclinical treatment strategies in pneumococcal meningitis.

One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopo

Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis

The SPEED (sepsis patient evaluation in the emergency department) score: a risk stratification and outcome prediction tool

Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes

Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey